文献类型：期刊文献

英文题名：CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future

作者：Zhang, Zhengchao[1,2];Li, Dong[1];Yun, Heng[1];Liu, Wei[1];Chai, Keqiang[1];Tong, Jie[1];Zeng, Tongwei[1];Gao, Zhenghua[1];Xie, Yongqiang[1]

第一作者：Zhang, Zhengchao

通信作者：Gao, ZH[1];Xie, YQ[1]

机构：[1]Gansu Univ Tradit Chinese Med, Affiliated Hosp 3, Dept Urol, Baiyin, Peoples R China;[2]Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Tradit Chinese Med, Affiliated Hosp 3, Dept Urol, Baiyin, Peoples R China.|[10735]甘肃中医药大学;

年份：2022

卷号：12

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-85134409256);WOS:【SCI-EXPANDED(收录号:WOS:000828327800001)】；

基金：This study was funded by the Third Affiliated Hospital of Gansu University of Chinese Medicine (Project Approval Number: 2016YG-06) and Baiyin City 2019 Science and technology plan project (Project Approval Number: 2019-1-22Y)

语种：英文

外文关键词：CAR-T cells; urologic neoplasms; kidney cancer; prostate cancer; bladder cancer; immunotherapy

摘要：In recent years, with the breakthrough of CAR-T cells in the treatment of hematological tumors, they are increasingly being used to treat solid tumors, including urologic neoplasms. There are many relatively specific targets for urologic neoplasms, especially prostate cancer. Besides, urologic neoplasms tend to progress more slowly than tumors in other organs of the body, providing ample time for CAR-T cell application. Therefore, CAR-T cells technology has inherent advantages in urologic neoplasms. CAR-T cells in the treatment of urologic neoplasms have been extensively studied and preliminary achievements have been made. However, no breakthrough has been made due to the problems of targeting extra-tumor cytotoxicity and poor anti-tumor activity. we systematacially summarized the research actuality of CAR-T cells in urologic neoplasms, discussed the potential value and difficulties of the research. The application of CAR-T cells in the treatment of urologic neoplasms requires improvement of function through screening for better targets, modification of CAR structures, or in combination with other antitumor approaches.